Clinical trials: Vasospastic Angina
Vasospastic Angina
The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris
Vasospastic angina is increasingly recognized as an important contributor to anginal symptoms in patients with non-obstructive coronary artery disease (ANOCA).
- Trial name
- ViVA (NCT06415227)
- Testing
- Vericiguat
- Where
- Netherlands
- Volunteers
- 57 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Angina Pectoris, Variant, Sudden Cardiac Death
Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death
The purpose of this study is to determine whether ICD(Implantable Cardioverter Defibrillator) implantation on the top of optimal medical therapy in patients with variant angina manifesting as aborted sudden cardiac death reduces…
- Trial name
- VARIANT ICD (NCT02845531)
- Testing
- Implantable Cardioverter Defibrillator, Optimal Medical Therapy
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Kee-joon Choi
Myocardial Ischemia, Non-Obstructive Coronary Atherosclerosis
Myocardial Ischemia Without Obstructive Coronary Stenoses
Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders.
- Conditions
- Myocardial Ischemia, Non-Obstructive Coronary Atherosclerosis, Microvascular Coronary Artery Disease, Vasospastic Angina
- Trial name
- NCT04827498
- Testing
- Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- Hospital San Carlos, Madrid
Microvascular Angina, Angina, Stable
iCorMicA - Stratified Medicine in Angina
The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry.
- Conditions
- Microvascular Angina, Angina, Stable, Ischemia With No Obstructive Coronary Arteries (INOCA), Coronary Microvascular Dysfunction (CMD)
- Trial name
- iCorMicA (NCT04674449)
- Testing
- Disclosure of IDP results, IDP performed but results not disclosed
- Where
- 39 sites in Ireland, Netherlands and 2 more
- Volunteers
- 1,500 people
- Sponsor
- NHS Greater Glasgow and Clyde
Angina Pectoris, Variant
Efficacy Study of Atorvastatin to Treat Variant Angina
The objective of this study is to evaluate effect of statin treatment for vasospastic angina.
- Trial name
- ESAVA (NCT00620204)
- Testing
- atorvastatin
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Samsung Medical Center
Variant Angina
Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina
The objective of this study is to investigate the efficacy and safety of Pletaal (Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel…
- Trial name
- STELLA (NCT01444885)
- Where
- 10 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Angina Pectoris, Variant, Statins, HMG-CoA
Statin Therapy In Patients With Vasospastic Angina
The purpose of this study is to evaluate whether statin is effective in the treatment of vasospastic angina.
- Trial name
- STAVA (NCT02790528)
- Testing
- Atorvastatin
- Where
- South Korea
- Sponsor
- Seung-Jung Park
Sleep Apnea, Obstructive, Hypoxia
"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"
The purpose of this study is to determine the factors that are associated with improved cardiovascular function with the use of CPAP therapy on subjects diagnosed with moderate to severe obstructive sleep apnea.
- Conditions
- Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders
- Trial name
- NCT01317329
- Testing
- Clinically prescribed CPAP therapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Wisconsin, Madison
Vasospastic Angina
Immunomodulatory Therapy & VSA
Vasospastic angina (VSA) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion.
- Trial name
- NCT06696807
- Testing
- glucocorticosteroids and/or intravenous immunoglobulin
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Dao Wen Wang
ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD)
Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women
This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology…
- Conditions
- ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD), Vasospastic Angina
- Trial name
- ANOCA-UY (NCT07593157)
- Testing
- Invasive Coronary Functional and Morphological Assessment, Pharmacological treatment will be individualized according to the invasive coronary phenotype identified. Treatment may include antianginal therapy, vasodilator therapy, endothelial function-targeted
- Where
- Uruguay
- Volunteers
- 50 people
- Sponsor
- Hospital de Clínicas Dr. Manuel Quintela
Vasospastic Angina
Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of MFDS.
- Trial name
- STELLA_Ext (NCT02094469)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Variant Angina
Cardioneuroablation for Variant Angina
Variant angina, also known as vasospastic angina, is a form of chest pain caused by temporary spasms of the coronary arteries, which reduce blood flow to the heart.
- Trial name
- NCT06992830
- Testing
- cardioneuroablation
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhibing Lu
Microvascular Angina, Vasospastic Angina
Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries
In patients with angina pectoris undergoing a coronary angiography (CAG) up to 40% do not have obstructive coronary artery disease (CAD).
- Trial name
- TENS-ANOCA (NCT06401291)
- Testing
- Transcutaneous Electrical Nerve Stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Vasospastic Angina
Multidetector Coronary CT In Vasospastic Angina
The purpose of this study is to compare the extent of coronary vessel stenosis between coronary spasm-induced angina attacks (named vasospastic angina, VSA) patients and health volunteers by multi-detector computed tomography…
- Trial name
- NCT02180971
- Testing
- Positive CAG with EG test, Negative CAG with EG test
- Where
- South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Vasospastic Angina
A Multi-Omics Study of Vasospastic Angina
This is a observational study to identify the key factor associated with vasospastic angina and to explore the prognosis of the participants.
- Trial name
- KIVAM (NCT05282511)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Angina Pectoris, Variant, Angina Pectoris; Spasm-Induced
ReACHallenge Trial: Acetylcholine Rechallenge After Pretreatment With Vasoactive Drugs
The goal of this clinical trial is to assess the feasibility and clinical value of acetylcholine (ACH) rechallenge after intracoronary verapamil +- nitroglycerine in a patient cohort with angina and non-obstructive coronary…
- Conditions
- Angina Pectoris, Variant, Angina Pectoris; Spasm-Induced, Angina Pectoris With Normal Coronary Arteriogram
- Trial name
- ReACHallenge (NCT05618132)
- Testing
- Acetylcholine rechallenge
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Antwerp
Quality of Life
Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina
The aim of the present study is to compare the effects of CCB and CCB+ high dose of statin therapy on the symptoms, function, and quality of life assessed by validated angina-specific questionnaire (Short-form Seattle Angina…
- Trial name
- SCARLET (NCT03054467)
- Testing
- Caduet 10Mg-20Mg Tablet, NorvasC® 10 mg Tablets
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kosin University Gospel Hospital
ANOCA, ANOCA - Angina With Non-obstructive Coronary Arteries
Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic
Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of…
- Conditions
- ANOCA, ANOCA - Angina With Non-obstructive Coronary Arteries, MINOCA, Microvascular Dysfunction
- Trial name
- CoroPhys-CZ (NCT07103317)
- Where
- Czechia
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Motol
Variant Angina
ANti-Oxidant in Variant Angina (ANOVA) Trial
Purpose Objectives 1. To evaluate the anti-oxidant effect of long-term Vitamin C+E therapy on coronary vasospasm improvement. 2. To evaluate the anti-oxidant effect of long-term statin therapy on coronary vasospasm improvement.
- Trial name
- NCT03228238
- Testing
- Vitamin C and Vitamin E, Statin, Standard medication for variant angina
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Seoul National University Hospital
Variant Angina
The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
The aim of the study was to to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina.
- Trial name
- NCT01674686
- Testing
- Sarpogrelate, Atorvastatin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center